OR WAIT null SECS
MMH Group
May 06, 2020
Conventional cleaning methods can risk product loss of biologics, prompting biopharmaceutical manufacturers to seek alternative criteria to validate cleaning processes.
May 02, 2020
Bioprocessing advances improve product yield, cut costs, and streamline integration between upstream and downstream processes.
April 02, 2020
Because conventional cleaning methods can risk product loss, biopharmaceutical manufacturers are often reluctant to use PDE/ADE limits to validate cleaning processes.
March 02, 2020
While new industry guidance documents issued by FDA speak to the agency’s efforts to promote the development of new gene therapies, certain hurdles remain to challenge stakeholders.
Tackling process development early on can better optimize manufacturing processes for emerging therapies.
The growing interest in developing cell and gene therapies has prompted industry investment to grow manufacturing capacity.